An internal audit at EuroAPI has uncovered potential misconduct leading to quality control issues. Production is on hold pending further investigation. Health authorities have been notified and a forensic audit is underway. Customers will be updated as more information becomes available.

The Brindisi site, which primarily produces anti-infective APIs, generated sales of 63 million euros in 2023, with 43% related to Sanofi. However, due to full impairment of its non-current assets in the 2023 accounts, the Group’s performance is expected to be impacted. As a result, the 2024 guidance is suspended, with a revised outlook to be provided in Q2 2024. This will coincide with updates on the FOCUS-27 project announced on February 28th, 2024.